

AGENDA

THURSDAY – JANUARY 28, 2016

- 2:00-2:10 PM Welcome and introduction
Owen A. O'Connor, MD, PhD
- 2:10-2:15 Introduction of keynote presenter
Kensei Tobinai, MD, PhD
- 2:15-3:00 Keynote address:
Randy D. Gascoyne, MD

SESSION 1: Epidemiology and Pathology of T-Cell Lymphoma

Moderators: TBA

- 3:00-3:20 The epidemiology of T-cell lymphoma in the Middle East
Hamdy A. Azim, MD
- 3:20-3:40 The epidemiology of T-cell lymphoma in Hong Kong and China
Yok-Lam Kwong, MD
- 3:40-4:00 Evolution of molecular classification of T-cell lymphoma
Stefano Pileri, MD, PhD
- 4:00-4:20 EBV-associated non-nasal T-cell lymphomas: Biology-based classification
Elaine S. Jaffe, MD
- 4:20-4:40 Putting the spectrum of ALCL into perspective: From indolent cutaneous to aggressive systemic disease
Andrew L. Feldman, MD
- 4:40-5:00 Break

SESSION 2: Clinical Extension of the Pathology of T-Cell Lymphoma

Moderators: TBA

- 5:00-5:20 Clinical approaches to EBV-associated T- or NK cell lymphoma
Won Seog Kim, MD
- 5:20-5:40 Update of HTLV-1 biology
Masao Matsuoko, MD
- 5:40-6:00 Development of companion diagnostics for T-cell lymphoma: The CD30 model
TBA
- 6:00-6:20 LGL – Biology to clinical syndrome
Thomas P. Loughran, Jr, MD
- 5:45-6:00 Panel Discussion
- 6:00-10:00 Welcome Dinner -

FRIDAY – JANUARY 29, 2016

- 7:00-8:00AM Continental Breakfast
- 8:00-8:05 Opening remarks:
Kensei Tobinai, MD, PhD

SESSION 3: Immuno-oncology in T-Cell Lymphoma

Moderators: TBA

- 8:05-8:25 Overview of immuno-oncology
James Allison, PhD
- 8:25-8:45 PD1: From basic biology to clinical application
Tasuku Honjo, MD, PhD
- 8:45-9:05 Targeting the microenvironment immunologic interface
TBA
- 9:05-9:25 Dendritic cell vaccine for ATL
Youko Suehiro, MD
- 9:25-9:40 Break

SESSION 4: CTCL: A Focused Update

Moderators: TBA

- 9:40-10:00 Pathology of CTCL
Pier Paolo Piccaluga, MD, PhD
- 10:00-10:20 Current treatment paradigms for CTCL
Francine M. Foss, MD
- 10:20-10:40 Whole-genome sequencing in mycosis fungoides
Laura Y. McGirt, MD
- 10:40-11:00 Genomic landscape of cutaneous T cell lymphoma
Jaehyuk Choi, MD, PhD
- 11:00-11:20 The emerging role of immunologic aspects of CTCL
Steven T. Rosen, MD,
- 11:20-11:40 What therapies for CTCL are on the horizon?
Madeleine Duvic, MD
- 11:40-12:00 Prognostic models and CTCL networks
Youn H. Kim, MD
- 12:00-2:00 Lunch Symposium:

SESSION 5: Molecular Pathways as Targets for T-Cell Lymphoma

Moderators: TBA

- 2:00-2:20 The relevancy of the PI3K pathway in TCL
- 2:20-2:40 The emerging data in support of targeting STAT 3 in PTCL
TBA
- 2:40-3:00 Targeting epigenetic
H. Miles Prince, MD, PhD
- 3:00-3:20 TCR signaling pathways: Are the therapeutic opportunities here
Steven M. Horwitz, MD

AGENDA

SESSION 6: Case Presentations with Pathology**Comments by Randy Gascoyne****Moderators: Randy D. Gascoyne, MD**

- 3:20-3:35 EATL-Type 2
TBA
- 3:35-3:50 Blastic NK T-cell lymphoma of the testicle
Ahmed Sawas, MD
- 3:50-4:05 Advanced peripheral T-cell lymphoma
Barbara Pro, MD
- 4:05-4:20 Case
TBA
- 4:20-4:50 Panel Discussants: Steve Rosen, Pier Luigi Zinzani, Yok Lam Kwong
- 4:50-5:05 Break

SESSION 7: Poster Presentations

Moderators: Francine M. Foss, MD
Owen A. O'Connor, MD, PhD
Kensei Tobinai, MD, PhD

- 5:05-6:00 TBD
- 6:00-8:00 **Poster Walk Reception**

SATURDAY – JANUARY 30, 2016

- 7:00-8:00 **Breakfast Symposium**
- 8:10-8:15 Opening remarks:
Francine M. Foss, MD

SESSION 8: New Approaches to Therapy for T-Cell Lymphoma**Moderators: TBA**

- 8:15-8:35 New agents in Japan
Kensei Tobinai, MD, PhD
- 8:35-8:55 Middle Eastern perspective: Can we cure adult T cell leukemia/lymphoma?
Ali Bazarbachi, MD
- 8:55-9:15 Integrating novel therapies into the therapy of T-cell lymphoma
Yuanki Shi, MD, PhD
- 9:15-9:35 Combination epigenetic platforms for T-cell lymphoma therapy
Owen A. O'Connor, MD
- 9:35-9:55 P-Gemox in NK
Huiqiang Huang, MD, PhD
- 9:55-10:15 Can we define the optimal patient populations for auto or allo transplant in PTCL?
Francesco A. d'Amore, MD, PhD
- 10:15-10:35 PTCL registry update
Massimo R. Federico, MD
- 10:35-10:50 Break

SESSION 9: Industry Perspectives**Moderators: TBA**

- 10:50-11:10 Targeting the apoptotic pathways
TBA
- 11:10-11:30 Trillium Therapeutics
Eric Sievers, MD
- 11:30-11:50 Kyowa Kirin: Global development of anti-CCR4: Update in 2016
Shiro Akinaga, PhD
- 11:50-12:10 TBA

SESSION 10: Wrap-up Highlights**Moderators: TBA**

- 12:10-12:15 United States
Steven T. Rosen, MD
- 12:15-12:20 Europe
Pier Luigi Zinzani, MD
- 12:20-12:25 Asia
Yok-Lam Kwong, MD
- 12:25-12:30 Closing remarks
Francine M. Foss, MD
- 12:30 Adjourn—Box lunch